CDK Global, Inc. Announces Initial Results of Its Tender Offers and Consent Solicitations, Receipt of Requisite Consents and Expiration of Withdrawal Rights and Extension of the Consent Time of the Tender Offer for Its 2024 Notes and the Expiration Date of each Tender Offer

Rhea-AI Summary

CDK Global announced initial results from its tender offers for three series of senior notes due 2024, 2027, and 2029. The Tender Offers are aimed at purchasing outstanding notes, with adjustments to interest rates, and amendments to the indentures governing the notes. As of May 3, 2022, over 57% of the 2024 notes, 81% of the 2027 notes, and nearly 98% of the 2029 notes were validly tendered. The Consent Time for 2024 Notes was extended to May 6, while the expiration date for all offers is now May 20, 2022. CDK anticipates completing a merger in Q3 2022.

Positive

• Over 57% of 4.500% Senior Notes due 2024, 81% of 4.875% Senior Notes due 2027, and nearly 98% of 5.250% Senior Notes due 2029 were validly tendered.
• The extension of the Consent Time and Expiration Date provides additional opportunity for noteholders to participate.

Negative

• The necessity of financing conditions for consummating the tender offers may imply uncertainty regarding completion.
• Potential risks associated with the merger completion scheduled for Q3 2022 may affect current offerings.

HOFFMAN ESTATES, Ill., May 04, 2022 (GLOBE NEWSWIRE) -- CDK Global, Inc. (Nasdaq: CDK) ("CDK" or the “Company”), a leading automotive retail technology company, today announced the initial results of and the receipt of required consents in connection with its previously announced tender offers (the “Tender Offers”) relating to any and all of its issued and outstanding 4.500% Senior Notes due 2024, the interest rate of which adjusts from time to time and is currently 5.000% (the “2024 Notes”), 4.875% Senior Notes due 2027 (the “2027 Notes”) and 5.250% Senior Notes due 2029 (the “2029 Notes” and, together with the 2024 Notes and the 2027 Notes, the “Notes”) pursuant to its Offer to Purchase and Consent Solicitation Statement dated April 20, 2022 (the “Offer to Purchase and Consent Solicitation Statement”). In addition, CDK today announced that it is extending the Consent Time (as defined below) of the Tender Offer relating to the 2024 Notes and the Expiration Date (as defined below) of each Tender Offer. In conjunction with the Tender Offers, CDK solicited from holders of the Notes consents (the “Solicitations”) to the adoption of proposed amendments to each of the indentures governing the Notes (together, the “Indentures”) to, among other things, eliminate any obligation to make a Change of Control Offer (as defined in the applicable Indenture), substantially all of the other restrictive covenants and certain events of default and other provisions (the “Proposed Amendments”).

The following table sets forth certain information regarding the Notes and the Tender Offers, including the percentage of the outstanding aggregate principal amount of each series of Notes that was validly tendered and not validly withdrawn on or prior to 5:00 P.M., New York City time, on May 3, 2022 (such time and date, as the same may be extended with respect to a Tender Offer, the "Consent Time"):

CUSIP Nos.		ISIN Nos.		Outstanding Principal Amount					Title of Security		Purchase Price(1)(2)				Consent Payment (1)(2)					Total Consideration(1)						Percentage of Principal Amount Tendered
12508EAD3		US12508EAD31		$500,000,000					4.500% Senior Notes due 2024(3)		$1,006.25				$30.00					$1,036.25						57.1%
12508EAF8		US12508EAF88		$600,000,000					4.875% Senior Notes due 2027		$982.50				$30.00					$1,012.50						81.0%
12508EAJ0 U12227AD3		US12508EAJ01 USU12227AD34		$500,000,000					5.250% Senior Notes due 2029		$982.50				$30.00					$1,012.50						97.9%

(1)	Per $1,000 principal amount of Notes and excluding Accrued Interest (as defined below), which will be paid in addition to the Total Consideration or Purchase Price, as applicable, up to the payment date.
(2)	Included in Total Consideration.
(3)	Original interest rate. Pursuant to the terms of the 2024 Notes, the interest rate adjusts from time to time and is currently 5.000%.

CDK has received the consents to the Proposed Amendments from holders of greater than a majority of the outstanding aggregate principal amount of each series of the Notes. Accordingly, the withdrawal deadline (with respect to a Tender Offer, the “Withdrawal Deadline”) for each series of the Notes has occurred and previously tendered Notes may no longer be withdrawn and consents may no longer be revoked, and holders who tender Notes after the Withdrawal Deadline will not have the right to withdraw such tendered Notes or to revoke consents to the adoption of the Proposed Amendments. The supplemental indentures to each Indenture governing the Notes were executed on May 3, 2022 (collectively, the “Supplemental Indentures”) and, as a result, the Proposed Amendments became effective; however, the Proposed Amendments will not become operative unless the tendered Notes have been accepted for purchase by CDK on the applicable acceptance date (with respect to a Tender Offer, the “Acceptance Date”) and the Acquisition (as defined below) has been consummated.

The Consent Time of the Tender Offer relating to the 2024 Notes has been extended from 5:00 P.M., New York City time, on May 3, 2022 to 5:00 P.M., New York City time, on May 6, 2022. In addition, the Expiration Date of each Tender Offer has been extended from 12:00 midnight, New York City time, at the end of the day on May 17, 2022 to 12:00 midnight, New York City time, at the end of the day on May 20, 2022, unless further extended (such time and date, as the same may be extended with respect to a Tender Offer, the “Expiration Date”). Except for the extension of the Consent Time of the Tender Offer relating to the 2024 Notes and the Expiration Date of each Tender Offer as described herein, all other terms and conditions of each Tender Offer and Solicitation remain unchanged. Holders that have previously tendered their Notes do not need to re-tender their Notes or take any other action in response to this amendment of the Tender Offers.

Holders of Notes who validly tendered (and did not validly withdraw) their Notes and validly delivered (and did not validly revoke) their corresponding consents at or prior to the Consent Time, and whose Notes are accepted for purchase, will receive the Total Consideration per $1,000 principal amount of Notes tendered, which includes a Consent Payment per $1,000 principal amount of Notes tendered, as set forth in the table above, plus any accrued and unpaid interest on the Notes up to, but not including, the settlement date (with respect to a Tender Offer, the “Settlement Date”), which is expected to promptly follow the Expiration Date. Holders who tender their Notes after the applicable Consent Time and on or prior to the applicable Expiration Date, and whose Notes are accepted for purchase, will receive the Purchase Price per $1,000 principal amount of Notes tendered set forth in the table above, but not the Consent Payment, plus any accrued and unpaid interest on the Notes up to, but not including, the Settlement Date. Upon the terms and conditions described in the Offer to Purchase and Consent Solicitation Statement, CDK will, promptly following the Expiration Date, accept for purchase all Notes validly tendered on or prior to the Expiration Date.

CDK undertook the Tender Offers and the Solicitations in connection with the Agreement and Plan of Merger, dated as of April 7, 2022, by and among Central Parent LLC, a Delaware limited liability company (the “Acquiror”), Central Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Acquiror (“Merger Sub”), and CDK, as amended from time to time, pursuant to which Merger Sub will be merged with and into CDK, with CDK surviving such merger as a wholly-owned subsidiary of the Acquiror (such transaction, the “Acquisition”). The Acquiror is an affiliate of Brookfield Asset Management Inc. and Brookfield Capital Partners VI L.P. CDK anticipates that the Acquisition will be completed in the third quarter of 2022 and intends to extend the applicable Expiration Date for each Tender Offer, without extending the related Withdrawal Deadline (unless required by law) to have the applicable Acceptance Date and Settlement Date coincide with the closing of the Acquisition.

If a Tender Offer is consummated and the Proposed Amendments become operative, the Notes subject to such Tender Offer that remain outstanding will not benefit from any of the restrictive covenants that are eliminated by the adoption of the Proposed Amendments and the Acquisition will not trigger the requirement that the Company make a Change of Control Offer under the applicable Indenture.

The consummation of a Tender Offer (including to pay the Consent Payment) remains conditioned upon (1) the receipt by CDK of net proceeds from a financing on terms and conditions satisfactory to CDK, which will be sufficient to fund the Total Consideration in respect of all applicable Notes (regardless of the actual amount of any Notes tendered) and estimated fees and expenses relating to such Tender Offer and Solicitation, (2) the consummation of the Acquisition and (3) satisfaction of certain other customary conditions. Holders who validly tender and do not validly withdraw their Notes prior to the Withdrawal Deadline and who validly deliver and do not validly revoke the corresponding consent at or prior to the applicable Consent Time and whose Notes are accepted for purchase will not be paid the Total Consideration (including the Consent Payment) or the Purchase Price, as applicable, until the applicable Settlement Date, and CDK's obligation to accept Notes for purchase and pay such amounts remain subject to the conditions described above.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders or consents with respect to, any security. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation or sale would be unlawful. The Tender Offers will only be made pursuant to the terms of the Offer to Purchase and Consent Solicitation Statement.

Holders may obtain copies of the Offer to Purchase and Consent Solicitation Statement from the Information Agent and Tender Agent for the Tender Offers, D.F. King & Co., Inc., at (212) 269-5550 (collect, for banks and brokers only) and (888) 540-8736 (toll free).

Credit Suisse Securities (USA) LLC is the Dealer Manager for the Tender Offers and Solicitation Agent for the Solicitations. Questions regarding the Tender Offers and Solicitations may be directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (toll free) and (212) 325-2476 (collect).

None of CDK, the Dealer Manager and Solicitation Agent, the Information Agent and Tender Agent or any other person makes any recommendation as to whether holders of Notes should tender their Notes or provide the related consents, and no one has been authorized to make such a recommendation.

About CDK Global, Inc.

With approximately $2 billion in revenues, CDK Global (NASDAQ: CDK) is a leading provider of retail technology and software as a service (SaaS) solutions that help dealers and auto manufacturers run their businesses more efficiently, drive improved profitability and create frictionless purchasing and ownership experiences for consumers. Today, CDK serves over 15,000 retail locations in North America.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. By their nature, forward-looking statements involve risks and uncertainty because they relate to events and depend on circumstances that will occur in the future, and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements include, among other things, statements about the ability of the parties to complete the proposed transaction and the expected timing of completion of the proposed transaction; as well as any assumptions underlying any of the foregoing.

The following are some of the factors that could cause actual future results to differ materially from those expressed in any forward-looking statements: (i) uncertainties as to the timing of, and the Company’s ability to complete, the Tender Offers and Solicitations, (ii) uncertainties as to the timing of the equity tender offer and the merger; (iii) the risk that the proposed transaction may not be completed in a timely manner or at all; (iv) uncertainties as to the percentage of the Company’s stockholders tendering their shares of common stock in the equity tender offer; (v) the possibility that competing offers or acquisition proposals for the Company will be made; (vi) the possibility that any or all of the various conditions to the consummation of the tender offer or the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (vii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, including in circumstances that would require the Company to pay a termination fee or other expenses; (viii) the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; (ix) risks related to diverting management’s attention from the Company’s ongoing business operations; (x) the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; and (xi) other factors as set forth from time to time in the Company’s filings with the SEC, including its annual report on Form 10-K for the fiscal year ended June 30, 2021 and any subsequent quarterly reports on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are based on information currently available to the Company, and the Company expressly disclaims any intent or obligation to update, supplement or revise publicly these forward-looking statements except as required by law.

Media Contacts: 
Tony Macrito
630.805.0782
Tony.Macrito@cdk.com

Investor Relations Contact:
Reuben Gallegos
847.542.3254
Reuben.Gallegos@cdk.com

 

FAQ

What is CDK's recent press release about the tender offers dated May 4, 2022?

CDK Global announced the initial results of its tender offers for its senior notes and extended the consent and expiration dates.

What are the results of CDK's tender offers for its senior notes?

As of May 3, 2022, 57.1% of 2024 notes, 81.0% of 2027 notes, and 97.9% of 2029 notes were tendered.

What is the new expiration date for the tender offers by CDK?

The expiration date for all tender offers has been extended to May 20, 2022.

What does the amendment to the indentures for the senior notes entail?

The amendment aims to eliminate several restrictive covenants and the obligation for CDK to make a Change of Control Offer.

When does CDK expect to complete the merger associated with the tender offers?

CDK anticipates completing the merger in the third quarter of 2022.